Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Net Margin: 2017-2025

Historic Net Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 16.23%.

  • Puma Biotechnology's Net Margin fell 899.00% to 16.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.11%, marking a year-over-year increase of 456.00%. This contributed to the annual value of 10.07% for FY2024, which is 90.00% up from last year.
  • Per Puma Biotechnology's latest filing, its Net Margin stood at 16.23% for Q3 2025, which was up 45.40% from 11.17% recorded in Q2 2025.
  • Puma Biotechnology's 5-year Net Margin high stood at 25.23% for Q3 2024, and its period low was -96.60% during Q3 2021.
  • Over the past 3 years, Puma Biotechnology's median Net Margin value was 10.33% (recorded in 2023), while the average stood at 8.46%.
  • As far as peak fluctuations go, Puma Biotechnology's Net Margin crashed by 3,461bps in 2021, and later soared by 9,597bps in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Net Margin stood at 7.63% in 2021, then slumped by 1,403bps to -6.40% in 2022, then surged by 2,339bps to 17.00% in 2023, then surged by 370bps to 20.70% in 2024, then crashed by 899bps to 16.23% in 2025.
  • Its last three reported values are 16.23% in Q3 2025, 11.17% for Q2 2025, and 6.46% during Q1 2025.